sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
carbamazepine
|
trimethoprim
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p39
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
mirtazapine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p26
|
It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.
|
anticoagulants
|
lovastatin
|
ADVISE
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s16
|
DDI-DrugBank.d567.s16.p0
|
Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.
|
INAPSINE
|
CNS depressant drugs
|
ADVISE
|
Droperidol_ddi.xml
|
DDI-DrugBank.d254.s2
|
DDI-DrugBank.d254.s2.p0
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
AKINETON
|
quinidine
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p15
|
Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
|
atorvastatin
|
atorvastatin
|
NONE
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s1
|
DDI-DrugBank.d140.s1.p4
|
Specific Effects of Felbatol on Other Antiepileptic Drugs Phenytoin: Felbatol causes an increase in steady-state phenytoin plasma concentrations.
|
Felbatol
|
phenytoin
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s11
|
DDI-DrugBank.d434.s11.p9
|
Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.
|
theophylline
|
enoxacin
|
EFFECT
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s22
|
DDI-DrugBank.d395.s22.p2
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
diazepam
|
thiazide diuretics
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p329
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
Serentil
|
prochlorperazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p166
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
tricyclic antidepressants
|
amitriptyline
|
NONE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p21
|
astemizole, bepridil, sparfloxacin, and terodiline.
|
astemizole
|
terodiline
|
NONE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s18
|
DDI-DrugBank.d237.s18.p2
|
Effects of Erythromycin on Felbatol The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.
|
Erythromycin
|
felbamate
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s36
|
DDI-DrugBank.d434.s36.p2
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
rifampin
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p8
|
While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
|
selective serotonin reuptake inhibitors
|
paroxetine
|
NONE
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s15
|
DDI-DrugBank.d77.s15.p3
|
Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
|
beta-adrenergic blocking agents
|
metoprolol
|
NONE
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s4
|
DDI-DrugBank.d325.s4.p4
|
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
|
HALDOL
|
CNS depressants
|
EFFECT
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s3
|
DDI-DrugBank.d186.s3.p5
|
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.
|
nevirapine
|
indinavir
|
NONE
|
11217868.xml
|
DDI-MedLine.d132.s4
|
DDI-MedLine.d132.s4.p6
|
H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
|
Proton Pump Inhibitors
|
H2 blockers
|
NONE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s11
|
DDI-DrugBank.d48.s11.p6
|
Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
|
NSAIDs
|
lithium
|
MECHANISM
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s9
|
DDI-DrugBank.d400.s9.p3
|
Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
|
clozapine
|
psychotropic drug
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s8
|
DDI-DrugBank.d480.s8.p13
|
Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
|
Epinephrine
|
glycosides
|
ADVISE
|
Epinephrine_ddi.xml
|
DDI-DrugBank.d247.s7
|
DDI-DrugBank.d247.s7.p1
|
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
|
androgens
|
insulin
|
EFFECT
|
Fluoxymesterone_ddi.xml
|
DDI-DrugBank.d355.s3
|
DDI-DrugBank.d355.s3.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Trileptal
|
morphine
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p416
|
Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
|
nitrous oxide
|
NIMBEX
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s6
|
DDI-DrugBank.d60.s6.p10
|
Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.
|
adrenaline
|
FLUOTHANE
|
ADVISE
|
Halothane_ddi.xml
|
DDI-DrugBank.d74.s2
|
DDI-DrugBank.d74.s2.p0
|
Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
|
ZYVOX
|
SSRIs
|
EFFECT
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s6
|
DDI-DrugBank.d441.s6.p3
|
Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
|
Clozapine
|
atropine
|
EFFECT
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s9
|
DDI-DrugBank.d480.s9.p1
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
dicumarol
|
olanzapine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p553
|
The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
|
mecamylamine
|
sympathomimetics
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s3
|
DDI-DrugBank.d448.s3.p6
|
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
|
Abciximab
|
Activase
|
EFFECT
|
Alteplase_ddi.xml
|
DDI-DrugBank.d508.s1
|
DDI-DrugBank.d508.s1.p14
|
The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and levothyroxine sodium.
|
phenobarbital
|
levothyroxine sodium
|
NONE
|
Buspirone_ddi.xml
|
DDI-DrugBank.d463.s7
|
DDI-DrugBank.d463.s7.p4
|
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
|
antiretroviral nucleoside analogues
|
nitrofurantoin
|
NONE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s13
|
DDI-DrugBank.d263.s13.p11
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
celecoxib
|
ramipril
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p46
|
Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.
|
succinylcholine
|
NIMBEX
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s3
|
DDI-DrugBank.d60.s3.p3
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
contraceptives
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p29
|
Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
|
benzodiazepines
|
alcohol
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s0
|
DDI-DrugBank.d18.s0.p2
|
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
|
Tagamet
|
tricyclic antidepressants
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s0
|
DDI-DrugBank.d171.s0.p6
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
ampicillin
|
Invirase
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p193
|
Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store.
|
Cytochalasin D
|
carbachol
|
EFFECT
|
11121387.xml
|
DDI-MedLine.d59.s5
|
DDI-MedLine.d59.s5.p0
|
Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.
|
NSAIDs
|
methotrexate
|
MECHANISM
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s1
|
DDI-DrugBank.d400.s1.p2
|
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.
|
PCP
|
PCP
|
NONE
|
11085328.xml
|
DDI-MedLine.d104.s8
|
DDI-MedLine.d104.s8.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
sodium colistemethate
|
anesthetics
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p107
|
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
|
citalopram
|
fluoxetine
|
NONE
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s8
|
DDI-DrugBank.d223.s8.p12
|
In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
|
INDOCIN
|
potassium-sparing diuretics
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s23
|
DDI-DrugBank.d82.s23.p1
|
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.
|
beta-blocker
|
reserpine
|
ADVISE
|
Levobunolol_ddi.xml
|
DDI-DrugBank.d252.s1
|
DDI-DrugBank.d252.s1.p0
|
Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
|
Netilmicin
|
loop diuretics
|
ADVISE
|
Netilmicin_ddi.xml
|
DDI-DrugBank.d417.s0
|
DDI-DrugBank.d417.s0.p0
|
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
|
itraconazole
|
gefitinib
|
MECHANISM
|
Gefitinib_ddi.xml
|
DDI-DrugBank.d207.s4
|
DDI-DrugBank.d207.s4.p3
|
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
|
quinidine
|
carvedilol
|
EFFECT
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s1
|
DDI-DrugBank.d269.s1.p14
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
levothyroxine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p22
|
MAO Inhibitors: DURAGESIC is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
|
MAOI
|
opioid analgesics
|
NONE
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s7
|
DDI-DrugBank.d170.s7.p8
|
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
|
Anticoagulants
|
platelet aggregation inhibitors
|
NONE
|
Ardeparin_ddi.xml
|
DDI-DrugBank.d105.s0
|
DDI-DrugBank.d105.s0.p0
|
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
|
benzodiazepines
|
monoamine oxidase inhibitors
|
EFFECT
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s1
|
DDI-DrugBank.d338.s1.p4
|
Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
|
phenothiazines
|
dopamine
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s7
|
DDI-DrugBank.d325.s7.p5
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
corticosteroids
|
dantrolene
|
NONE
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p65
|
Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
|
corticosteroid
|
inactivated vaccines
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s30
|
DDI-DrugBank.d314.s30.p4
|
Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.
|
amprenavir
|
methadone
|
EFFECT
|
Amprenavir_ddi.xml
|
DDI-DrugBank.d437.s9
|
DDI-DrugBank.d437.s9.p3
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
sympathomimetic agents
|
progestogens
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p58
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
Levo-Dromoran
|
antihistamines
|
EFFECT
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p11
|
Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
|
escitalopram
|
Celexa
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s39
|
DDI-DrugBank.d568.s39.p8
|
In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
|
Angiomax
|
thrombolytics
|
EFFECT
|
Bivalirudin_ddi.xml
|
DDI-DrugBank.d569.s1
|
DDI-DrugBank.d569.s1.p2
|
If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.
|
rifampicin
|
isradipine
|
MECHANISM
|
Isradipine_ddi.xml
|
DDI-DrugBank.d81.s10
|
DDI-DrugBank.d81.s10.p0
|
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
|
atorvastatin
|
erythromycin
|
NONE
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s9
|
DDI-DrugBank.d140.s9.p4
|
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
|
efavirenz
|
CANCIDAS
|
MECHANISM
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s12
|
DDI-DrugBank.d350.s12.p4
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
haloperidol
|
contraceptives
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p719
|
Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
|
Isoflurane
|
nondepolarizing muscle relaxants
|
EFFECT
|
Isoflurane_ddi.xml
|
DDI-DrugBank.d227.s0
|
DDI-DrugBank.d227.s0.p1
|
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
Dexbrompheniramine
|
alcohol
|
INT
|
Dexbrompheniramine_ddi.xml
|
DDI-DrugBank.d62.s0
|
DDI-DrugBank.d62.s0.p0
|
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure.
|
Sildenafil
|
long-acting nitrates
|
ADVISE
|
11213561.xml
|
DDI-MedLine.d1.s5
|
DDI-MedLine.d1.s5.p0
|
Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
|
Netilmicin
|
furosemide
|
ADVISE
|
Netilmicin_ddi.xml
|
DDI-DrugBank.d417.s0
|
DDI-DrugBank.d417.s0.p1
|
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.
|
magnesium
|
magnesium
|
NONE
|
7786695.xml
|
DDI-MedLine.d103.s1
|
DDI-MedLine.d103.s1.p9
|
In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.
|
doxazosin
|
cimetidine
|
MECHANISM
|
Doxazosin_ddi.xml
|
DDI-DrugBank.d367.s4
|
DDI-DrugBank.d367.s4.p0
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
antidepressants
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p0
|
Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.
|
ketoconazole
|
VIDEX
|
ADVISE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s5
|
DDI-DrugBank.d43.s5.p1
|
Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
|
erythromycin
|
ergotamine
|
EFFECT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s5
|
DDI-DrugBank.d397.s5.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
quinidine
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p13
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
indomethacin
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p22
|
Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
|
Sonata
|
cimetidine
|
MECHANISM
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s29
|
DDI-DrugBank.d324.s29.p0
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
glimepiride
|
salicylate
|
ADVISE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p1
|
For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters
|
anticoagulant
|
Bezalip
|
ADVISE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s1
|
DDI-DrugBank.d291.s1.p0
|
Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
|
nonsteroial anti-inflammatory drugs
|
cyclosporine
|
MECHANISM
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s18
|
DDI-DrugBank.d132.s18.p3
|
Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.
|
Antizol
|
ethanol
|
MECHANISM
|
Fomepizole_ddi.xml
|
DDI-DrugBank.d228.s0
|
DDI-DrugBank.d228.s0.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
ranitidine
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p43
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
|
thiazides
|
phenothiazines
|
NONE
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s1
|
DDI-DrugBank.d536.s1.p2
|
The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.
|
potassium-sparing antihypertensives
|
NSAIDs
|
EFFECT
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s11
|
DDI-DrugBank.d20.s11.p0
|
Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.
|
Digitalis
|
Bretylium Tosylate
|
EFFECT
|
Bretylium_ddi.xml
|
DDI-DrugBank.d180.s0
|
DDI-DrugBank.d180.s0.p0
|
The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies.
|
NovoSeven
|
coagulation factor
|
NONE
|
Coagulation factor VIIa_ddi.xml
|
DDI-DrugBank.d221.s0
|
DDI-DrugBank.d221.s0.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
vitamin K
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p9
|
Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.
|
Combination hormonal contraceptives
|
selegiline
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s39
|
DDI-DrugBank.d485.s39.p2
|
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone.
|
everolimus
|
prednisone
|
NONE
|
11180038.xml
|
DDI-MedLine.d140.s2
|
DDI-MedLine.d140.s2.p1
|
Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.
|
INDOCIN
|
digoxin
|
ADVISE
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s22
|
DDI-DrugBank.d82.s22.p0
|
Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.
|
Diuretics
|
diuretics
|
NONE
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s0
|
DDI-DrugBank.d176.s0.p0
|
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
|
tetracyclines
|
penicillins
|
EFFECT
|
Ampicillin_ddi.xml
|
DDI-DrugBank.d211.s2
|
DDI-DrugBank.d211.s2.p14
|
Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.
|
Etofibrate
|
heparin
|
EFFECT
|
11166779.xml
|
DDI-MedLine.d44.s6
|
DDI-MedLine.d44.s6.p0
|
It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.
|
ethambutol
|
antacids
|
NONE
|
Ethambutol_ddi.xml
|
DDI-DrugBank.d160.s1
|
DDI-DrugBank.d160.s1.p1
|
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin.
|
NaFlu
|
insulin
|
NONE
|
11154900.xml
|
DDI-MedLine.d76.s1
|
DDI-MedLine.d76.s1.p26
|
Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
|
eplerenone
|
saquinavir
|
MECHANISM
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s3
|
DDI-DrugBank.d20.s3.p2
|
Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively).
|
estradiol
|
noradrenaline
|
EFFECT
|
11213358.xml
|
DDI-MedLine.d102.s5
|
DDI-MedLine.d102.s5.p0
|
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
|
midazolam
|
Aprepitant
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s23
|
DDI-DrugBank.d382.s23.p3
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
adrenocortical steroids
|
ethchlorvynol
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p33
|
Antineoplastic agents (e. g., nitrogen mustard, etc.) should be given concomitantly only with great caution.
|
Antineoplastic agents
|
nitrogen mustard
|
NONE
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s1
|
DDI-DrugBank.d318.s1.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.